Home > Healthcare > Pharmaceuticals > Finished Drug Form > Myeloproliferative Disorders Drugs/Treatment Market

Myeloproliferative Disorders Drugs/Treatment Market Trends

Report ID: GMI8372
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Myeloproliferative Disorders Drugs/Treatment Market Trends

Growing focus on R&D activities by the pharmaceutical and biotech companies has significantly propelled the growth of the myeloproliferative disorder treatment.
The escalated research to address the patient's need for effective treatment options has led to the discovery and development of innovative therapeutic approaches, including targeted therapies like JAK inhibitors, that offer improved efficacy and tolerability profiles.
For instance, in May 2023, PharmaEssentia announced the commencement of its ECLIPSE PV Phase IIIb clinical trial for ropeginterferon alfa-2b-njft (BESREMi) in treating polycythemia vera.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of myeloproliferative disorders drugs/treatment reached USD 9.3 billion in revenue in 2023 and is set to witness 3.2% CAGR through 2032, driven by the increasing availability of novel drugs worldwide.

The JAK inhibitors segment is anticipated to witness 3.1% CAGR over 2024-2032, owing to the growing research on introducing effective treatments for the rare hematological disorder.

North America market accounted for 41.9% revenue share in 2023, owing to the presence of advanced healthcare infrastructure and facilities in the region.

Some top myeloproliferative disorders drugs/treatment firms are AbbVie Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc (GSK), GL Pharma Gmb, Incyte Corporation, Janssen Biotech, Inc. (Johnson & Johnson), MorphoSys AG, Mylan N.V. (Viatris), Novartis Pharmaceuticals Corporation (Novartis AG), Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.